This significant progression free survival benefit was retained in patients with moderate to strong CLDN18.2 expression in > 70% of tumor cells (95% CI 0.23–0.62; HR 0.38) (Sahin et al. 2021). The gene discussed is CLDN18; the disease is neoplasm.